Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

30-10-2017 | Image

Figure 2: Time elapsed (in days) from the start of allopurinol treatment to the occurrence of allopurinol hypersensitivity syndrome in patients with gout. [27]

The median time from the start of therapy to reaction was 30 days, and 90% of reactions occurred within 180 days. Reproduced with permission from Stamp, L. K. et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 64, 2529–2536(2012) © 2012, American College of Rheumatology.

print
PRINT
Image Credits